Intravitreal Bevacizumab for Diabetic Macular Edema

Isfahan Ophthalmology Research Center0 个研究点开始时间: 2008年6月23日最近更新: 2008年6月23日

适应症

试验速览

阶段: 2 期
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.

This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.

研究设计

研究类型: Interventional

入排标准

性别: All
接受健康志愿者: 否

入选标准

•Diabetes mellitus
•Clinically significant macular edema
•Possibility of performing macular OCT
•Consent of patient for inclusion in the study

排除标准

•History of macular photocoagulation in less than 6 months of inclusion in the study
•Necessity of surgical intervention
•Rejection of the remaining in the study by patient

研究者

发起方

Isfahan Ophthalmology Research Center

申办方类型

Network

相似试验

已完成

不适用

Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular EdemaDiabetic Macular Edema

NCT01342159Hallym University Medical Center80

已完成

不适用

Short-term Effects of Intravitreal Bevacizumab and Triamcinolone in Patients With Diabetic Macular EdemaDiabetic Macular Edema

NCT00563940Insel Gruppe AG, University Hospital Bern30

撤回

3 期

Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular EdemaDiabetes Mellitus Type 2Diabetic Macular Edema

NCT00417716Asociación para Evitar la Ceguera en México

已完成

4 期

Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMODiabetic Macular EdemaDiabetic Retinopathy

NCT04619303Lions Eye Institute, Perth, Western Australia59

Unknown

3 期

Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)Diabetic Retinopathy

NCT00370721Shahid Beheshti University of Medical Sciences